Mobile

We Provide Advanced Technology-Enabled Oncology Clinical Trial Services

We believe every cancer patient deserves the best chance to receive world-class healthcare options.

Contact Us What is Our Virtual Command Center?
I am interested in
Clinical Trial Matching

All cancer patients deserve equal access to the latest in cancer care therapies and treatments. Refer a patient, friend, family member or loved one to get in touch with Massive Bio.

Refer a Patient
Pre-Screening

Massive Bio can improve your efficiency and patient satisfaction scores by pre-screening all cancer patients at your practice, at no cost to you. Patients are pre-screened with AI based technology for trials and advanced care options with sub-specialist and case management support.

Pre-screen Patients
Be Part of Our Oncologist Network

Join our growing network of key opinion leaders and oncologists. Your knowledge, research, and expertise in cancer treatment can make a difference.

Join Our Physician Network

Other services we provide

Just In Time Activation

Multi-disciplinary background of experts like surgeons, radiation oncologists, pathologists, and medical oncologists gather to discuss treatment options for individual cancer patients.

EMR Activation

Instant access to patient EMR lets trial sites receive lab results, radiology reports, and even X-ray images electronically while ensuring tests are not duplicated. Machine learning technology for scaled pre-screening; prescreening in the matter of seconds instead of hours. Submit patient records digitally to expedite the pre-screening for the Synergy-AI clinical trial matching process.

Browse Recruiting Trials

Content 1
Myelofibrosis

A phase III randomized, double-blind, placebo-controlled study in participants with Myelofibrosis

Phase III Study
Age +18
Gender Male & Female
Content 2
Follicular Lymphoma/Marginal Zone Lymphoma

A phase III randomized, double-blind, placebo-controlled, multicenter study in patients with relapsed/refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Phase III Study
Age +18
Gender Male & Female
Content 3
Prostate Cancer

A phase III randomized study for patients with stage IV adenocarcinoma of the prostate with no prior treatment for metastatic disease.

Phase III Study
Age +18
Gender Male
Content 4
Stage IV Pancreatic Cancer

A phase III, randomized study for patients with stage IV adenocarcinoma of the pancreas with no prior treatment for metastatic disease

Phase III Study
Age +18
Gender Female & Male
Content 5
HER2 Positive Solid Tumors, GE junction, Gastric Cancer

A Phase I/II, open-label, multicenter study in patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

Phase III Study
Age +18
Gender Female & Male
Content 6
Alteration/Biomarker-Positive Solid Tumors

A Phase II study in patients with Alteration/Biomarker-Positive Advanced or Metastatic Solid Tumors

Phase III Study
Age +18
Gender Female & Male
Content 7
Breast Cancer FGFR

A phase II, non-randomized clinical trial for patients with Metastatic Breast Cancers Harboring FGFR Amplifications

Phase III Study
Age +18
Gender Female
Content 8
Cervical Cancer

A phase II randomized study in women with Recurrent/Persistent/Metastatic Cervical Cancer who have progressed following first-line therapy

Phase III Study
Age +18
Gender Female
Content 9
Follicular Lymphoma/Marginal Zone Lymphoma

A phase III randomized, double-blind, placebo-controlled study in patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Phase III Study
Age +18
Gender Male & Female
Content 10
Mantle Cell Lymphoma

A phase III randomized, double-blind study for the treatment of Newly Diagnosed Mantle Cell Lymphoma

Phase III Study
Age +18
Gender Male & Female
Content 11
Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

A phase 1b/2a basket study in adult patients with Relapsed/Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Phase 1b/2a Study
Age +18
Gender Male & Female
Content 12
Non-Small Cell Lung Cancer MET

A first-in-human/phase I/II study for patients with Non-Small Cell Lung Cancer with MET Alteration

Phase I/II Study
Age +18
Gender Male & Female
Healthcare
Provider Platform
Login

Please get in touch with our team for more details

Contact form

    Physician Details




    Patient has been informed that Massive Bio will be contacting them

    Patient Details





    Your personal data is fully confidential and 100% secure


      How many patients you need to have pre-screen service?

      Your personal data is fully confidential and 100% secure

      Pre-Screening Requests Form


        Your personal data is fully confidential and 100% secure

        Join Our Oncologist Network Form